For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
MINT has developed the Endolumenal Surgical Platform (ESP), a revolutionary medical device that will enable GI surgeries to be performed endolumenally – entirely from within the channel of the intestine – reducing anesthesia, shortening hospital stays, reducing healthcare costs, accelerating patient recovery, and improving clinical outcomes. ESP is the first step in MINT’s goal to migrate all GI surgeries to endolumenal procedures, opening an entirely new field of endolumenal GI surgery.
ESP is a stabilized endolumenal platform that expands the capabilities of currently available tools and enables complex minimally invasive endolumenal procedures.
Figure: ESP passing the flexure with the aft balloon (top left), Improved visualization in the flexure (top right), Established Therapeutic Zone (lower left), Manipulating bowel to optimize polyp access for treatment (lower right)
Proof of Concept In Vitro: Improved Visualization - (40% increase in visible area)
In the hands of colorectal surgeons and interventional endoscopists, ESP as designed, working in conjunction with currently available endoscopes and instruments, will enable advanced procedures to be performed endolumenally. This will dramatically improve outcomes compared to open or laparoscopic procedures by reducing surgical trauma and accelerating recovery, meanwhile driving significant cost out of the healthcare system. ESP-enabled procedures will spare 200,000 patients per year from invasive surgical procedures to treat their difficult polyps, and ESP could save $650M to the US Healthcare system per year just for the treatment of difficult polyps.
ESP in its current form is MINT’s first step in enabling complex endolumenal surgeries for a wider range of target applications. Pipeline developments include advanced tools that will leverage ESP’s stable platform and provide better surgical capabilities. This will enable the development of endolumenal approaches for additional therapeutic areas such as diverticular disease, stricture, intestinal fistulae, prolapse, volvulus, anastomosis leaks and early cancers.